Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: better outcomes with busulfan and melphalan …
Autologous stem cell transplantation remains a clinical option to consolidate some adult
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission—better outcomes after busulfan and melphalan compared with busulfan and …
BACKGROUND Autologous stem cell transplantation (ASCT) for adult acute myelogenous
leukemia (AML) is a valid therapeutic option for patients with good‐risk and intermediate …
leukemia (AML) is a valid therapeutic option for patients with good‐risk and intermediate …
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with …
We retrospectively compared the impact of the conditioning regimen in adult patients with
acute myeloid leukemia (AML) in first complete remission (CR1) that received high-dose …
acute myeloid leukemia (AML) in first complete remission (CR1) that received high-dose …
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: an analysis from the Acute Leukemia Working Party …
Allogeneic hematopoietic cell transplantation is a potentially curative treatment in patients
with acute myeloid leukemia. Recent advances in the field of hematopoietic cell allografting …
with acute myeloid leukemia. Recent advances in the field of hematopoietic cell allografting …
Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and …
R Fedele, G Messina, T Martinello, GA Gallo… - … Myeloma and Leukemia, 2014 - Elsevier
Background The aim of this study was to compare safety and efficacy of the association of
busulfan with cyclophosphamide (BuCy2) versus busulfan and fludarabine (BuFlu) as a …
busulfan with cyclophosphamide (BuCy2) versus busulfan and fludarabine (BuFlu) as a …
Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus …
Purpose Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan
(Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell …
(Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell …
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute …
SS Farag, BJ Bolwell, PJ Elder, M Kalaycio… - Bone marrow …, 2005 - nature.com
To reduce relapse following allogeneic transplantation for AML, intensification of high-dose
busulfan/cyclophosphamide using additional agents has been investigated but with few …
busulfan/cyclophosphamide using additional agents has been investigated but with few …
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with …
A Rambaldi, A Grassi, A Masciulli, C Boschini… - The lancet …, 2015 - thelancet.com
Background The standard busulfan–cyclophosphamide myeloablative conditioning regimen
is associated with substantial non-relapse mortality in patients older than 40 years with …
is associated with substantial non-relapse mortality in patients older than 40 years with …
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and …
Y Shimomura, M Hara, S Hirabayashi… - Bone Marrow …, 2021 - nature.com
The prognosis of refractory and relapsed acute myeloid leukemia (R/R AML) is dismal with
the 2-year overall survival (OS) being~ 20%[1]. Salvage chemotherapy alone offers almost …
the 2-year overall survival (OS) being~ 20%[1]. Salvage chemotherapy alone offers almost …
Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects
The use of autologous stem cell transplantation (ASCT) as consolidation therapy for adult
patients with acute leukemia has declined over time. However, multiple randomized studies …
patients with acute leukemia has declined over time. However, multiple randomized studies …